As of November 10, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Fate Therapeutics Inc. The largest reported stake is Redmile Group, LLC's, at 14.99%. 8 filings are on record since July 3, 2025 (Schedule 13D/A, November 9, 2026).
Sell to companies like Fate Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Redmile Group, LLC · Sole voting: 0 · Shared voting: 19,164,572 · Sole dispositive: 0 · Shared dispositive: 19,164,572 · SCHEDULE 13D/A, 2026-11-09
- · Reporting person: BlackRock, Inc. · Sole voting: 2,194,284 · Shared voting: 0 · Sole dispositive: 2,194,284 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-08
- · Holder: Redmile Group, LLC · Percent: 14.9% · SCHEDULE 13D/A
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-26
- · Reporting person: Schonfeld Strategic Advisors LLC · Sole voting: 937,521 · Shared voting: 0 · Sole dispositive: 937,521 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-08-14
Fate Therapeutics Inc has 8 Schedule 13D or 13G filings on record since 2025-07-03. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Redmile Group, LLC | 14.99% | 19,164,572 | SCHEDULE 13D/A, 2026-11-09 | 2026-11-05 |
| The Goldman Sachs Group, Inc. | 2% | 2,274,020 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| BlackRock, Inc. | 1.9% | 2,194,284 | SCHEDULE 13G/A, 2026-07-08 | 2026-06-30 |
| Schonfeld Strategic Advisors LLC | 0.82% | 937,521 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Fate Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Fate Therapeutics Inc and the records around it.
Fate Therapeutics Inc elsewhere on the record
Companies that share a holder
- Schonfeld Strategic Advisors LLC also filed stake reports on 5 other companies: Inhibrx Biosciences, Inc. (Aug 2026), Cardinal Infrastructure Group Inc. (May 2026), Jiuzi Holdings, Inc. (Feb 2026)
- Redmile Group, LLC also filed stake reports on 18 other companies: Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026), Nurix Therapeutics, Inc. (Aug 2026)
- THE GOLDMAN SACHS GROUP, INC. also filed stake reports on 173 other companies: AEON ACQUISITION I CORP. (Nov 2026), ALPEX ACQUISITION CORPORATION (Nov 2026), ARCHIMEDES TECH SPAC PARTNERS II CO. (Nov 2026)
Watch Fate Therapeutics Inc
Get an email when Fate Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Fate Therapeutics Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Fate Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fate Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Redmile Group, LLC | 0 | 19,164,572 | 0 | 19,164,572 | SCHEDULE 13D/A, 2026-11-09 |
| Jeremy C. Green | 0 | 19,164,572 | 0 | 19,164,572 | SCHEDULE 13D/A, 2026-11-09 |
| RedCo II Offshore SPV LLC | 0 | 10,144,307 | 0 | 10,144,307 | SCHEDULE 13D/A, 2026-11-09 |
| Redmile Capital Offshore II Master Fund, Ltd. | 0 | 6,426,298 | 0 | 6,426,298 | SCHEDULE 13D/A, 2026-11-09 |
| BlackRock, Inc. | 2,194,284 | 0 | 2,194,284 | 0 | SCHEDULE 13G/A, 2026-07-08 |
| Schonfeld Strategic Advisors LLC | 937,521 | 0 | 937,521 | 0 | SCHEDULE 13G/A, 2025-08-14 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-26 |
The latest filing identifies Fate Therapeutics Inc by CUSIP 31189P102 and gives its principal executive office as 12278 Scripps Summit Drive, San Diego, CA 92131 (SCHEDULE 13D/A, 2026-11-09).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-03 | Redmile Group, LLC | 14.9% | SCHEDULE 13D/A |
| 2025-07-29 | The Vanguard Group | 7.64% | SCHEDULE 13G/A |
| 2025-08-14 | The Goldman Sachs Group, Inc. | 2% | SCHEDULE 13G/A |
| 2025-08-14 | Schonfeld Strategic Advisors LLC | 0.82% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-22 | Redmile Group, LLC | 14.9% | SCHEDULE 13D/A |
| 2026-07-08 | BlackRock, Inc. | 1.9% | SCHEDULE 13G/A |
| 2026-11-09 | Redmile Group, LLC | 14.99% | SCHEDULE 13D/A |
Questions about who owns Fate Therapeutics Inc
Who owns Fate Therapeutics Inc?
On this page, one holder's latest ownership filing reports 5% or more of Fate Therapeutics Inc: Redmile Group, LLC (14.99%, Schedule 13D/A, filed 2026-11-09).
When did Redmile Group, LLC buy into Fate Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Redmile Group, LLC on this page is the Schedule 13D/A, filed 2025-07-03, reporting 14.9%; its latest, Schedule 13D/A filed 2026-11-09, reports 14.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Fate Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.